<DOC>
	<DOCNO>NCT02362269</DOCNO>
	<brief_summary>The propose study randomize , double-blind , control , multi-center clinical trial six month daily oral vitamin D3 ( cholecalciferol ) . This study randomize 334 community-dwelling post-menopausal woman European African descent ( ~167 ancestry ) 1:1 ratio control arm dose algorithm arm use stratified block randomization block size six stratification site ( ancestry ) . The sample size 334 include 10 % over-recruitment allow loss follow-up . The European ancestry woman see Madison clinic African ancestry woman see Milwaukee clinic . The propose study focus post-menopausal woman subset population Dr. Engelman 's Dr. Binkley 's preliminary data drawn . Moreover , 25 ( OH ) D concentration typically low woman old individual , since production vitamin D skin follow sun exposure decrease age . Therefore , group individual likely benefit vitamin D supplementation , especially personalize base biology use propose dose algorithm .</brief_summary>
	<brief_title>Personalized Vitamin D Supplementation European African Americans</brief_title>
	<detailed_description>Potential volunteer screen telephone . Those meet inclusion exclusion criterion invite screen study visit . At screening , informed consent obtain . The study team collect follow determine study eligibility : basic demographic information ( age , ancestry , education ) ; medical history ; medication supplement use ; blood screen 25 ( OH ) D calcium test . At baseline , participant randomly assign control dose algorithm group . Both participant study staff contact participant blind group assignment . Follow-up visit occur three six month . At baseline follow-up visit , height weight measure blood drawn vitamin D panel , calcium , PTH . Blood DNA body composition obtain baseline visit . Participants ask return unused study supplement compliance assess follow-up visit pill count . The control group receive 2500 IU vitamin D3 daily dose algorithm group initially receive 1000 , 2500 , 4000 IU daily , initial dose base 25 ( OH ) D baseline , dose may adjust 3-month visit .</detailed_description>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Healthy , communitydwelling postmenopausal woman selfreported European ( Madison site ) African ( Milwaukee site ) descent Able willing sign inform consent Baseline serum 25 ( OH ) D concentration 10.029.9 ng/mL Willing alter amount baseline vitamin D supplementation course study Willing use sunscreen ( SPF ≥15 ) sun exposure &gt; 15 minute expect month May September Diagnosis kidney liver disease ( organs metabolize vitamin D ) Current hypercalcemia ( serum calcium ≥ 10.5 mg/dL ) disorder may affect vitamin D metabolism predispose hypercalcemia , i.e. , sarcoidosis , active tuberculosis granulomatous disease . Other chronic disease condition potentially affect vitamin D metabolism absorption ( inflammatory bowel disease , cystic fibrosis , ulcerative colitis , malabsorptive surgery ) History nephrolithiasis Current use medication affect vitamin D metabolism ( glucocorticoid , anticonvulsant , antifungal , HIV/AIDS medication ) History form cancer within past two year exception basal squamous cell skin lesion , situ tumor thyroid cancer Terminal illness/on hospice Severe endorgan disease ( e.g. , cardiovascular , pulmonary , etc . ) , may limit ability complete study Treatment high dose vitamin D ( ≥50,000 IU weekly ) active metabolite vitamin D , e.g. , calcitriol , within six month screen ; current use multiple vitamin vitamin D supplement allow . Use tan bed salon unwillingness utilize sunscreen period sun exposure 15 minute longer May September Planned trips/vacations likely associate substantial amount sun exposure course study ( i.e. , 500 mile south Madison/Milwaukee )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>